Is it correct to say that based on the previous announcement, of the 6 that have been assessed, 3 have achieved a partial response, and therefore the run rate on partial responses is 50%
If that trajectory continues, then 50% > 23% so there would be a fairly compelling argument that the FAK inhibitor is incrementally impactful?
i guess then its a question of how that plays out from a valuation perspective. Surely the company would look to do a deal rather than going solo on a Ph3 trial?
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-18
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
-0.005(3.23%) |
Mkt cap ! $41.21M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.0¢ | 15.0¢ | $20.04K | 130.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 104907 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 23481 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| ATX (ASX) Chart |